NUVB Stock Recent News

Nuvation Bio is a Buy after FDA approval of Ibtrozi, a highly selective ROS1+ NSCLC treatment with strong clinical results and brain metastasis efficacy. Ibtrozi demonstrated superior response rates and progression-free survival compared to established TKIs, positioning it as a leading contender in a growing market. Financials are solid with $247M cash, low price-to-book, and a conservative $700M peak sales projection, suggesting the stock is undervalued entering commercialization.

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in three upcoming investor conferences, including fireside chats at two conferences: Cantor Global Healthcare Conference 2025 on Thursday, September 4, 2025,.

After reaching an important support level, Nuvation Bio Inc. (NUVB) could be a good stock pick from a technical perspective. NUVB recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.15 per share a year ago.

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “With FDA approval of IBTROZI, we're proud of our swift evolution into a commercial‐stage company executing across functions to deliver a differentiated therapy to 70 patients in just seven weeks,” said David Hung, M.D., Founder, President, an.

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio websi.

Nuvation Bio (NUVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZI™) has been added as a Preferred Agent in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Non-Small Cell Lung Cancers (NSCLC), updated on June 20. Specifically, the NCCN Guidelines® now include taletrectinib (IBTROZI) as a Preferred.

LOUISVILLE, Ky., June 16, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Nuvation Bio Inc. for IBTROZI™ (taletrectinib), a kinase inhibitor approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)1. This indication was approved based on the Phase 2 TRUST-I and TRUST-II studies of taletrectinib that enrolled over 300 patients with ROS1-positive NSCLC.2 ,3

The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of lung cancer.